Pharmaceuticals

Latest Market Developments in Migraine Drugs Industry: Forecast 2025–2029

September 1, 2025 by Marketing Posting

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Are the Latest Market Insights for the Migraine Drugs Industry?#_x000D_

The market for vutrisiran has seen swift expansion in recent times. It is predicted to rise from $0.6 billion in 2024 to $0.67 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.8%. The substantial growth in the past can be linked to heightened awareness about hereditary transthyretin amyloidosis, increasing number of clinical trials, higher healthcare expenditure, a greater patient inclination towards non-invasive administration techniques, and an upswing in genetic disorders._x000D_

_x000D_

The market size for vutrisiran is projected to experience sharp expansion in the forthcoming years. It is predicted to augment up to “$1.06 billion in 2029 at a compound annual growth rate (CAGR) of 12.0%. The surge during the forecast period can be ascribed to factors such as the expansion of healthcare facilities, higher occurrence of chronic illnesses, amplified funding for research and development, heightened focus on personalized medicine, and growing knowledge of disease. Noteworthy trends observed within the forecast period comprise advancements in combination therapies, uptake of targeted therapies, progress in tailored medicine, evolution in digital health tech, and breakthroughs in biotech._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21320&type=smp_x000D_

_x000D_

#What Forces Are Driving The Growth Of The Migraine Drugs Industry?#_x000D_

The escalating number of females worldwide is projected to bolster the progress of the migraine drugs market in the coming years. The term ‘female population’ pertains to all females of different age groups residing within a country or region during a particular timeframe. Migraines are notably more prevalent in females than males, a situation attributed to a mix of genetic, hormonal, and environmental aspects. As an example, the World Population Prospects 2022, disseminated by the US-based intergovernmental organization United Nations, suggests that the global female populace in 2022 is likely around 4.00 billion, accounting for 49.75% of the global populace. It is furthermore projected that the number of females will surpass males by 2049. Consequently, the surge in the female populace is fueling the expansion of the migraine drugs market._x000D_

_x000D_

The vutrisiran market covered in this report is segmented – _x000D_

_x000D_

1) By Drug Class: Antisense Oligonucleotide, Nucleic Acids, Nucleotide, Nucleoside, Other Drug Classes_x000D_

2) By Route Of Administration: Oral, Injectable, Subcutaneous_x000D_

3) By Patient Demographics: Pediatric, Adult, Geriatric_x000D_

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels_x000D_

_x000D_

Subsegments:_x000D_

1) By Antisense Oligonucleotide: Single-Stranded Antisense Oligonucleotides, Double-Stranded Antisense Oligonucleotides _x000D_

2) By Nucleic Acids: DNA-based Nucleic Acids, RNA-based Nucleic Acids _x000D_

3) By Nucleotide: Purine Nucleotides, Pyrimidine Nucleotides _x000D_

4) By Nucleoside: Purine Nucleosides, Pyrimidine Nucleosides _x000D_

5) By Other Drug Classes: Peptide-Based Drugs, Protein Therapeutics_x000D_

_x000D_

#What Long-Term Trends Are Likely To Affect The Migraine Drugs Market?#_x000D_

The vutrisiran market is primarily trending towards the advancement of innovative therapeutic options, such as subcutaneous RNAi treatments, aimed at providing more user-friendly and less frequently required dosage methods for the control of inherited transthyretin-mediated (hATTR) amyloidosis. Treatments involving subcutaneous RNAi leverage RNA interference technology and are injected beneath the skin, intended for protracted release. This strategy guarantees stable medication levels over a period of time, thereby enhancing patient convenience and adherence in the treatment of polyneuropathy connected with inherited transthyretin-mediated (hATTR) amyloidosis. For example, Alnylam Pharmaceuticals, a biopharmaceutical company based in the US, declared in June 2022 that vutrisiran (trade name AMVUTTRA) had received approval from the Food and Drug Administration (FDA), and was effective in treating polyneuropathy in adults suffering from inherited transthyretin-mediated (hATTR) amyloidosis. It drastically makes the symptoms of neuropathy better and stops the advancement of the disease. In the HELIOS-A Phase 3 study, it was found that the disease progression was reversed or halted in over 50% of the population. AMVUTTRA exhibits an optimistic safety profile, without any withdrawals or deaths related to the medication, and a dosing process that could enhance patient adherence._x000D_

_x000D_

#Who Are The Primary Players Operating Across The Global Migraine Drugs Market?#_x000D_

Major companies operating in the vutrisiran market are Alnylam Pharmaceuticals Inc _x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/vutrisiran-global-market-report_x000D_

_x000D_

#Which Region Offers The Most Growth Potential For The Migraine Drugs Market Through 2029?#_x000D_

North America was the largest region in the vutrisiran market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vutrisiran market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21320&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_